CytoSorbents Corporation (CTSO) CEO Phillip Chan on Q1 2021 Results - Earnings Call TranscriptSeeking Alpha • 05/05/21
U.S. FDA Approves CytoSorbents to Initiate U.S. STAR-T Trial For Ticagrelor Removal During Cardiothoracic SurgeryPRNewsWire • 04/19/21
CytoSorbents Announces Lease of New Global Headquarters in Princeton, New JerseyPRNewsWire • 03/29/21
CytoSorbents Announces Filing of an Investigational Device Exemption (IDE) for U.S. Trial on Ticagrelor Removal During Cardiothoracic SurgeryPRNewsWire • 03/16/21
Cytosorbents' (CTSO) CEO Phillip Chan on Q4 2020 Results - Earnings Call TranscriptSeeking Alpha • 03/10/21
CytoSorbents to Present at the 10th Annual SVB Leerink Global Healthcare ConferencePRNewsWire • 02/16/21
National Institute for Health and Care Excellence (NICE) Issues Medtech Innovation Briefing on CytoSorb for Reducing Risk of Bleeding During Cardiac SurgeryPRNewsWire • 02/04/21
CytoSorbents Appoints David D. Cox, PhD, MBA as Vice President - Global Regulatory AffairsPRNewsWire • 01/21/21
CytoSorbents Announces Approval of CytoSorb® in Korea in Collaboration with Partner Fresenius Medical CarePRNewsWire • 01/19/21
CytoSorbents Promotes Dr. Christian Steiner to Executive Vice President of Sales and MarketingPRNewsWire • 12/17/20
Early CytoSorb Initiation Improves Hemodynamic Stabilization and Survival in New Septic Shock StudyPRNewsWire • 12/09/20
CytoSorbents Launches International Campaign to Raise $100,000 for the Global Humanitarian Organization, CAREPRNewsWire • 12/02/20
CytoSorbents Highlights Largest Published Case Series To Date Using CytoSorb in Critically Ill COVID-19 PatientsPRNewsWire • 11/25/20